Skip to main content
. Author manuscript; available in PMC: 2012 Nov 9.
Published in final edited form as: Sci Transl Med. 2012 Apr 25;4(131):131ra50. doi: 10.1126/scitranslmed.3003623

Fig. 8.

Fig. 8

Reversal of APD and QT prolongation and EADs by mexiletine. (A) Representative action potentials recorded in canine myocytes treated with or without 500 nM BEZ235 in the presence or absence of mexiletine (4 μg/ml) for 2 hours. (B) Summary data of APD90 are shown in the graph. n = 10 cells for each group. (C) EADs induced by 5 μM ISO in BEZ235-treated myocytes. (D) Summary data of percentage of cells with EADs. n = 10 cells for each condition. (E) Representative ECG tracings from WT and p110α−/− (α−/−) hearts before and after addition of mexiletine (4 μg/ml) to the circulating bath. (F) QT interval corrected for heart rate (QTc) from three hearts in each group.